Palvella Therapeutics Rings the Opening Bell

About This Event

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Wes Kaupinen, Founder and Chief Executive Officer, rings the Opening Bell.